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Abstract
Background: Cognitive function is a key determinant of independence and quality of life among older adults. Compared
to adults in England, US adults have a greater prevalence of cardiovascular risk factors and disease that may lead to poorer
cognitive function. We compared cognitive performance of older adults in the US and England, and sought to identify
sociodemographic and medical factors associated with differences in cognitive function between the two countries.
Methods: Data were from the 2002 waves of the US Health and Retirement Study (HRS) (n = 8,299) and the English
Longitudinal Study of Ageing (ELSA) (n = 5,276), nationally representative population-based studies designed to facilitate
direct comparisons of health, wealth, and well-being. There were differences in the administration of the HRS and ELSA
surveys, including use of both telephone and in-person administration of the HRS compared to only in-person
administration of the ELSA, and a significantly higher response rate for the HRS (87% for the HRS vs. 67% for the ELSA).
In each country, we assessed cognitive performance in non-hispanic whites aged 65 and over using the same tests of
memory and orientation (0 to 24 point scale).
Results: US adults scored significantly better than English adults on the 24-point cognitive scale (unadjusted mean: 12.8
vs. 11.4, P < .001; age- and sex-adjusted: 13.2 vs. 11.7, P < .001). The US cognitive advantage was apparent even though
US adults had a significantly higher prevalence of cardiovascular risk factors and disease. In a series of OLS regression
analyses that controlled for a range of sociodemographic and medical factors, higher levels of education and wealth, and
lower levels of depressive symptoms, accounted for some of the US cognitive advantage. US adults were also more likely
to be taking medications for hypertension, and hypertension treatment was associated with significantly better cognitive
function in the US, but not in England (P = .014 for treatment × country interaction).
Conclusion: Despite methodological differences in the administration of the surveys in the two countries, US adults
aged ≥ 65 appeared to be cognitively healthier than English adults, even though they had a higher burden of cardiovascular
risk factors and disease. Given the growing number of older adults worldwide, future cross-national studies aimed at
identifying the medical and social factors that might prevent or delay cognitive decline in older adults would make
important and valuable contributions to public health.
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Cognitive function is a key determinant of independence
and quality of life among older adults.[1] Recent demo-
graphic, medical and social trends in both the United
States and England are likely to have had an important
impact on the cognitive health of older adults in both
countries. For instance, a recent study reported that adults
in the United States were much more likely to have hyper-
tension, obesity, diabetes, and heart disease than adults in
England, [2] and there is growing evidence that these car-
diovascular risks are also risks for cognitive impairment
and dementia among older adults. [3-5] Other important
developments over the past two decades on both sides of
the Atlantic, such as more effective treatments for hyper-
tension and high cholesterol, new medications for the
treatment of Alzheimer's disease, lifestyle changes such as
use of cigarettes and alcohol, and rising levels of educa-
tion and wealth may also have had an impact on cognitive
health and function among older adults in the United
States and England.[6] At the same time, the organization
and level of funding of the health care systems in the two
countries are strikingly different, with per capita health
care expenditures in the United States nearly 2.5 times
higher than in the United Kingdom ($5,700 in the US vs.
$2,300 in the UK).[7]
International comparisons of cognitive health have been
made difficult by the lack of comparable data on cognitive
functioning in different countries. We report here the first
comparison of cognitive function in the United States and
England, using the same cognitive measures administered
to nationally representative samples of older adults in
both countries. Our research questions were: 1) Are there
differences in cognitive function among adults aged 65
and older in the two countries; and 2) If so, are there dif-
ferences in demographic, socioeconomic or health meas-
ures across the two countries that account for the
difference in cognitive function?
Methods
Data and Study Populations
We used data from the 2002 waves of the Health and
Retirement Study (HRS) and the English Longitudinal
Study of Ageing (ELSA). The HRS and ELSA are biennial,
longitudinal, nationally representative surveys of, respec-
tively, US adults aged 51 and older, and English adults
aged 50 and older.[8,9] The two studies were developed
collaboratively with significant overlap in survey ques-
tions in order to facilitate valid cross-national compari-
sons of aging-related changes in health, wealth, and well-
being. More detail on the studies, including all survey
questions, can be found at the HRS[10] and ELSA[11] web
sites.
For this study, we included individuals who were aged 65
and older. To maximize the comparability of the US and
English samples, we only included respondents of white
race since ELSA contains very few (n = 156) non-white
individuals. We also excluded individuals represented by
a proxy (1,171 [12%] in the HRS and 96 [2%] in the
ELSA) since the cognitive tests were not administered to
these respondents. The overall response rate among all eli-
gible respondents was 87% for the 2002 HRS and 67% for
ELSA. The final study samples included 8,299 individuals
from the HRS and 5,276 individuals from the ELSA.
Both the HRS and ELSA studies include population
weights that can be used to draw valid inferences for the
entire US and English age 65+ populations, respectively.
In the HRS, weights are constructed in a two-step process,
where the first step develops post-stratified household
weights using the initial sampling probabilities for each
household, as well as birth year, race/ethnicity, and gen-
der of household members. The second step uses these
household weights to then construct post-stratified
respondent-level weights which are scaled to yield weight
sums corresponding to the number of individuals in the
US population as measured by the US Census Bureau's
Current Population Survey (CPS) for the month of March
in the year of data collection.
ELSA study participants were drawn from the Health Sur-
vey for England, which has an equal probability sample
design, so weights to account for selection probabilities
are not needed. However, weighting is needed to take into
account household and individual non-response which
was done by analyzing stage and extent of drop-out from
the study, and took into account factors including region
of residence, age of oldest person, household size, social
class, and incidence of longstanding illness. This informa-
tion was used in logistic regression models to predict non-
response probability and the resulting values were
inverted for responding households to provide an initial
non-response weight. A second round of weighting was
used to adjust the initial household non-response weights
to ensure the weighted sample matched the English pop-
ulation as assessed by the 2001 National Census. Full
details on the development of population weights for the
HRS and ELSA studies are available at the study web-
sites[10,11].
The HRS survey was administered by telephone (71% of
the sample) and in-person (29% of the sample). The HRS
attempts to interview older respondents (age ≥ 80) in-per-
son whenever possible. All ELSA interviews were per-
formed in-person.
Measurement of Cognitive Function in the HRS and ELSA
Both the HRS and ELSA assessed cognitive function using
tests of immediate and delayed recall of 10 common
nouns. A list of ten words was presented orally to study
participants, who were then asked to recall as many wordsPage 2 of 11
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again after an approximately five-minute delay during
which they completed other survey questions. The same
four randomly assigned lists of 10 nouns were used in
both the HRS and ELSA. Orientation to the day, date,
month, and year were also assessed in the same way in
both the HRS and ELSA. These three tests resulted in a cog-
nitive scale ranging from 0 to 24 possible points (10
points for immediate recall, 10 points for delayed recall,
and 4 points for orientation). If a respondent refused to
provide an answer for any of the 3 tests, they were
assigned a score of "0" for that test. Ninety-five (1%) HRS
respondents and 43 (1%) ELSA respondents refused to
answer for one or more of the cognitive tests. Detailed
information on the cognitive measures used in this analy-
sis, including their derivation, reliability, and validity, is
available at the HRS website.[12]
Measures of Health Conditions, Risk Factors, and 
Treatments
Participants in the both the HRS and ELSA were asked
about the presence of common chronic health conditions
using the question, "Has a doctor ever told you that you
had...?" For this analysis, we included stroke, diabetes,
heart disease, hypertension, lung disease, and cancer.
Depressive symptoms experienced in the last week were
assessed using an 8-item version of the Center for Epide-
miologic Studies Depression (CES-D) scale.[13] The 8-
item version of the CES-D scale used in the HRS and ELSA
has comparable reliability and validity to the widely used
and validated 20-item CES-D Scale.[13,14].
Smoking status (never, former, or current), and alcohol
consumption (average number of days/week that alcohol
was consumed over the last 3 months [HRS] or 12 months
[ELSA]) were assessed similarly in both the HRS and ELSA.
Among those who reported hypertension or diabetes, cur-
rent use of prescription medications to treat these condi-
tions was determined. (Diabetes treatments were
categorized as none, oral medications only, and insulin)
The HRS and ELSA determine the presence of limitations
in independent function by asking about difficulty with 6
activities of daily living (ADLs; eating, getting in and out
of bed, toileting, dressing, bathing, walking across a
room) and 5 instrumental activities of daily living (IADLs;
preparing meals, grocery shopping, making phone calls,
taking medications, managing money).[15]
Sociodemographic Measures
We included age (65 – 74, 75 – 84, ≥ 85), gender, house-
hold net worth (tertiles; 2002 US dollars) and level of
education as sociodemographic measures in the analyses.
British pounds were converted to 2002 US dollars using
the average currency exchange rate for 2002.[16] Measures
of education differ in the HRS and ELSA. Following Banks
and colleagues, [2] we identified low, middle, and high
education categories for each country (0 to 12 years of
school, 13 to 15 years, and ≥ 16 years, respectively, in the
US; qualified to lower than "Ordinary-level" [O-level], O-
level to lower than "Advanced-level" [A-level], and A-level
or higher, respectively, in England).
Analysis Plan
We calculated scores for the 3 individual cognitive tests
(immediate recall, delayed recall, and orientation) as well
as for the combined 24-point scale. Mean scores for the
full sample, and for age-, gender-, and education-stratified
samples for the US and England were compared using t-
tests.
We then pooled data from the US and England and esti-
mated an ordinary least squares (OLS) regression model
with total cognitive score as the dependent variable. A
dichotomous variable indicating the country (0 for Eng-
land; 1 for the US) was used to determine cross-national
differences in cognitive function, after accounting for soci-
odemographic and health variables. We estimated 8 sepa-
rate linear regression models with different sets of
independent variables (e.g., demographic variables,
chronic health conditions, hypertension and diabetes
treatments, depressive symptoms) in order to determine
which variables were associated with US – English differ-
ences in cognitive score.
All analyses used the HRS or ELSA population weights to
adjust for survey non-response and for the complex sam-
pling design (stratification and clustering) of each study.
The University of Michigan Medical School Institutional
Review Board (IRB) reviewed this study and determined
that it was exempt from IRB review since all data used for
the study were publicly available.
Results
Characteristics of the US and English Study Populations
Table 1 shows the characteristics of the US and English
cohorts. The US cohort included a slightly higher propor-
tion of women. Educational attainment was significantly
higher in the US, as was average household net worth (in
2002 US dollars). The English cohort reported signifi-
cantly lower levels of chronic disease for every condition
included in the analysis, with strikingly lower prevalence
for a number of conditions. For instance, only 9% of Eng-
lish adults reported a diagnosis of diabetes compared to
16% of the US adults. Similarly, 45% of English adults
reported hypertension, compared to 57% of US adults,
while only 8% reported cancer in England compared to
18% in the US.
Despite lower levels of chronic disease, English adults
reported more limitations in ADLs and IADLs, as well asPage 3 of 11
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Table 1: Characteristics of the US and English cohorts, age 65+, 2002
Variable US
(N = 8,299)
England
(N = 5,276)
P value*
Age .07
65 – 74 51.2 54.0
75 – 84 38.4 35.9
≥ 85 10.4 10.2
Mean ± SE 75.0 ± .14 74.7 ± .12 .06
Gender <.001
Male 40.5 42.9
Female 59.5 57.1
Education** <.001
Low 61.3 70.7
Middle 18.9 10.9
High 19.8 18.4
Net worth (2002 US Dollars) .01
≤ $83,000 29.0 33.5
$83,001 – $318,000 34.9 33.1
> $318,000 36.1 33.4
Mean ± SE 357,700 ± 17,500 251,800 ± 6,400 <.001
Chronic Conditions
Stroke 8.0 6.9 .03
Diabetes 16.4 9.0 <.001
Heart disease 30.9 28.6 .01
Hypertension 56.6 44.8 <.001
Lung disease 11.3 8.1 <.001
Cancer 17.6 8.0 <.001
# of ADLs† impaired <.001
0 77.9 71.9
1 – 3 19.2 24.4
4 – 6 2.9 3.7
Mean ± SE .44 ± .02 .55 ± .02 <.001
# of IADLs‡ impaired <.001
0 86.5 82.6
1 – 3 12.4 16.3
4 – 5 1.1 1.1
Mean ± SE .23 ± .01 .28 ± .01 .001
CES-D (Depressive symptoms) <.001
0 43.6 36.6
1 – 3 41.8 45.9
4 – 8 14.6 17.5
Mean ± SE 1.5 ± .04 1.7 ± .03 <.001
Treatment with medications:
Hypertension (n = 4,664) (n = 2,368)
90.5 84.9 <.001
Diabetes (n = 1,389) (n = 480)
No diabetes treatment 19.7 26.5 .003
Only oral medication 62.4 54.2
Insulin +/- oral med 17.9 19.3
Alcohol intake (days/week) <.001
0 53.9 15.5
< 1 15.2 33.5
>1 to 2 13.7 24.3
>2 17.2 26.6
Smoking Status <.001
Never 42.8 35.2
Former 47.7 52.5
Current 9.5 12.3
Values are weighted percentages or means derived using the HRS and ELSA respondent population weights to adjust for the complex sampling 
design of each survey.
* P value of chi-square or t-test for a significant difference in proportion or mean between countries.
† ADLs indicates Activities of Daily Living (eating, transferring, toileting, dressing, bathing, and walking across a room).
‡ IADLs indicates Instrumental Activities of Daily Living (preparing meals, grocery shopping, making phone calls, taking medications, managing 
money).
**Education categories – US: Low- ≤ 12 years of school; Mid- 13 to 15 years; High- ≥ 16 years. England: Low- lower than "O-level" (typically 0 to 11 
years of school); Mid- "O-level" to lower than "A-level" (typically 12 to 13 years); High- "A-level" or higher (typically > 13 years). Categories based 
on Banks et al 2006. [2]
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sion or diabetes, US adults were significantly more likely
to be taking medications for these conditions. English
adults were more likely to be current smokers and drank
on more days per week than those in the US.
Cognitive Function in the US and England
Unadjusted mean scores, as well as age- and sex-adjusted
means, for each cognitive test, by country, are shown in
Table 2. Overall, English adults performed significantly
worse on the combined 24-point cognitive scale, scoring
1.4 points lower than US adults (a 12% relative difference,
P < .001). Performance on the delayed recall test showed
the greatest difference between countries, with English
adults scoring 1.0 points lower than US adults on the 10-
point scale (24% relative difference, P < .001). Perform-
ance on immediate recall was also significantly worse in
England, while scores for orientation were similar in the
two countries. Differences between the US and England
for the age- and sex-adjusted means were similar to the
unadjusted values. Figure 1 shows a frequency plot of the
distribution of scores on the combined 24-point scale in
each country.
Table 3 shows cognitive performance in the US and Eng-
land, stratified by age, gender, and education. As expected,
cognitive performance was generally worse among older
individuals in both countries, but the age-related differ-
ence in cognitive performance was more significant in
England (P = .03 for Age × Country interaction). For
instance, the mean score for the combined cognitive scale
among English adults was 12.5 for the youngest age group
(65–74) and 8.3 for the oldest age group (85+) (4.2
points, a 34% relative difference), while the mean scores
in the youngest and oldest group in the US were 13.8 and
10.1, respectively (3.7 points, 27% relative difference).
The largest US-English difference in total cognitive score
was, therefore, in the oldest age group (1.8 point US-Eng-
lish difference for those 85+, compared to a 1.3 point dif-
ference for those 65–74).
Table 4 reports the results of 8 different OLS regression
models with the combined 24-point cognitive score as the
dependent variable, using pooled data from the US and
England. The country variable in the first row of the table
represents the cognitive performance of US adults com-
pared to English adults (reference group). Model 1 shows
the unadjusted 1.43 point difference in mean score
between US and English adults already noted in Table 2.
Higher levels of education and net worth (Model 3) in the
US accounted for some of the better cognitive perform-
ance in the US (coefficient on the country variable
decreased from 1.46 to 1.30). While hypertension treat-
ment was associated with significantly better cognitive
performance (Model 5, 0.56 points) and hypertension
treatment was more common in the US than England, this
did not account for a large part of the US-English cognitive
performance difference when holding sociodemographic
and cardiovascular risks constant (country coefficient
decreased from 1.35 to 1.33). The higher prevalence of
depressive symptoms in England accounted for the great-
est proportion of the poorer cognitive performance in
England compared to the US (country coefficient
decreased from 1.33 to 1.16 with the addition of controls
for depressive symptoms in Model 6). Drinking alcohol
was associated with better cognitive function compared to
those who reported no alcohol intake. English adults were
more likely to drink some alcohol, so the addition of con-
trols for alcohol intake resulted in an increase in the US-
English difference in adjusted cognitive score (country
coefficient increased from 1.16 to 1.43 between Models 6
and 7). In the fully adjusted model (Model 8), being in
the oldest age group was associated with the biggest dec-
rement in cognitive function, while female gender and
high levels of education were associated with the largest
increment in cognitive function. Stroke and hypertension
were also associated with significantly poorer cognitive
function, while treatment with anti-hypertensive medica-
tion was associated with significantly better cognitive
function.
Discussion
In this first international comparison of cognitive func-
tion in nationally representative samples of older adults
in the United States and England, US adults performed
better than their English counterparts. Using the same
Table 2: Cognitive function in the US and England, age 65+, 2002
Unadjusted Age- and Sex-Adjusted
Cognitive Test US
(N = 8,299)
England
(N = 5,276)
P Value* US
(N = 8,299)
England
(N = 5,276)
P Value*
Immediate Recall (Mean ± SE) 5.1 ± .03 4.7 ± .03 <.001 5.3 ± .04 4.8 ± .04 <.001
Delayed Recall 4.1 ± .03 3.1 ± .03 <.001 4.3 ± .05 3.3 ± .05 <.001
Orientation 3.6 ± .01 3.6 ± .01 .2 3.6 ± .02 3.6 ± .02 .2
Combined Scale 12.8 ± .06 11.4 ± .06 <.001 13.2 ± .09 11.7 ± .08 <.001
* P value of t-test for a significant difference in mean between countries.Page 5 of 11
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showed significantly better performance on standard tests
of memory. The US cognitive advantage was greatest for
the "oldest-old," those aged 85 and older. On a popula-
tion level, the overall difference in cognitive performance
between the two countries was quite large, approaching
the magnitude associated with about 10 years of aging.
The better cognitive performance of US adults in our study
was surprising since, as was found for younger adults aged
55–64 in a recent report, [2] we found that older US adults
had a significantly higher prevalence of cardiovascular risk
factors (hypertension and diabetes), heart disease, and
stroke. Since increasing evidence suggests that cardiovas-
cular risk factors and cardiovascular disease are associated
with cognitive decline and poorer cognitive function,
[4,17] the higher burden of these conditions among US
adults would seem to predict poorer cognitive function
compared to English adults with a lower burden of these
conditions.
What might account for the apparently better "brain
health" among older US adults compared to English
adults in the face of a significantly higher burden of cardi-
ovascular risk factors and disease? Our study suggests a
number of possibilities. First, US adults had significantly
higher levels of education and wealth than English adults
in 2002, and these factors accounted for some of the bet-
ter US cognitive performance in our multivariable analy-
ses. More years of formal education is associated with a
reduced risk of cognitive decline and dementia, [18,19]
likely through multiple causal pathways, including a
direct effect on brain development and function, [20] bet-
ter health behaviors, [21,22] more cognitively stimulating
occupations, [19,23] and a safer and more enriched social
environment.[24] Greater wealth is also associated with
better cognitive function, likely sharing many of the same
causal pathways with education.[6,25]
Another interesting and important difference between
US and English adults that may have accounted for some
of the US cognitive advantage was the significantly lower
level of depressive symptoms reported by US adults.
Depression is associated with worse cognitive function,
although this relationship is likely complex and bidirec-
tional, with depression possibly being a risk factor for
cognitive decline, and early cognitive decline possibly
leading to depressive symptoms.[26] We found a signif-
icant dose-response relationship between the number of
reported depressive symptoms and cognitive perform-
ance, with those reporting 4 to 8 depressive symptoms
scoring nearly 1 point lower on the cognitive scale in our
fully adjusted model (Model 8 in Table 4). In our multi-
variable models, the greater prevalence of depressive
symptoms in England explained a portion of the poorer
cognitive performance among older English adults. Mak-
ing valid comparisons of the prevalence of diagnosed
clinical depression in different countries is difficult due
to differences in study populations and diagnostic crite-
ria. A study of depression prevalence among adults in
European countries found significant international vari-
ation, from about 9% in Iceland to 24% in Ger-
many.[27] In England, depression prevalence was 10%
in a sample from Liverpool and 17% in London. In the
United States a large community-based study in the early
1990s found a 10% prevalence of depression among
adults.[28] Interestingly, and perhaps important to the
interpretation of our findings, fewer than 15% of
depressed adults in these English samples were receiving
medication to treat their depression, while a study of US
adults during the same time period (mid-1990s), found
that nearly 75% of depressed individuals were receiving
medication therapy.[29] Future research should explore
whether more widespread use of anti-depressant medica-
tion in the United States may be one reason for the lower
level of depressive symptoms, and in turn, the better cog-
nitive performance of older adults in the US compared to
England that we found in our study.
One significant difference in health behaviours between
the US and England – the consumption of alcohol – likely
favoured the cognitive performance of older adults in
England. We have previously reported that moderate alco-
hol consumption, compared to abstinence, was associ-
ated with better cognition among those aged 50 and older
in the 2002 wave of the ELSA.[30] We found a similar pos-
itive relationship between alcohol consumption and cog-
nition in those aged 65 and older, with those reporting
some alcohol intake showing significantly better cognitive
function than those who reported abstaining from drink-
Distribution of scores on the 24-point combined cognitive scale, y countryFigure 1
Distribution of scores on the 24-point combined cog-
nitive scale, by country.Page 6 of 11
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alcohol intake compared to only 15.5% of English adults.
Finally, while US adults reported a higher prevalence of
hypertension, they also were more likely to be taking
medications to treat hypertension (91% vs. 85% of those
with hypertension, p < .001). This finding is in line with a
prior cross-national study of hypertension treatment in
the 1990's showing a greater likelihood of any hyperten-
sion treatment among hypertensive US adults (age 35 to
64) compared to English adults, as well as more aggressive
blood pressure lowering among those being treated (84%
of treated US adults had a blood pressure of < 160/95
compared to 73% of English adults).[31] A number of
observational studies have shown a relationship between
hypertension and an increased risk for cognitive impair-
ment, [3,32] as well as a protective effect of antihyperten-
sive therapy for preventing cognitive decline.[33,34]
Similarly, in our study self-reported use of antihyperten-
sive medications was associated with significantly better
cognitive function, controlling for all other covariates.
However, while some randomized controlled trials of
antihypertensive therapy have shown a benefit for cogni-
tive function, [35] other RCTs have not shown a clear ben-
efit.[36]
To test the hypothesis that more aggressive and effective
hypertension treatment in the US vs. England (among
those receiving treatment) might be contributing to the
US cognitive advantage, we performed an additional
regression analysis limited to those with hypertension.
After controlling for all of the variables in our analysis
(Model 8), an interaction term for hypertension treatment
× country (England as reference) was positive (coefficient
= 0.64 points) and statistically significant (P = .014). In
this sub-analysis, hypertension treatment in the US was
associated with a 0.5 point higher cognitive score (among
those with hypertension, after controlling for all other
covariates), while hypertension treatment in the UK was
associated with a 0.1 point lower cognitive score. Future
research with more detailed data on hypertension treat-
ment (e.g., number of medications, type of medications,
and dose of medications) and measured blood pressure is
required to better assess whether more aggressive hyper-
tension treatment in the US is, in fact, helping to protect
cognitive function more effectively than in England.
The fact that the greatest cognitive advantage for US adults
in our study was among the oldest-old may also support
the hypothesis that more aggressive diagnosis and treat-
ment of hypertension, and possibly other cardiovascular
risks, in the US in middle-age and older adults leads to less
significant cognitive decline among the oldest-old. Given
the significant public health and cost implications of cog-
nitive decline and the incidence of dementia in aging pop-
ulations around the world, future research to identify
Table 3: Cognitive function in the US and England, age 65+, by selected variables, 2002
Immediate Recall Delayed Recall Orientation Combined
Variable US England US England US England US England
Age
65 – 74 5.6 5.2 4.6 3.6 3.6 3.7 13.8 12.5
75 – 84 4.9 4.3 3.6 2.6 3.7 3.6 12.2 10.5
≥ 85 4.0 3.4 2.7 1.6 3.5 3.3 10.1 8.3
* Test
(Age × Country)
.1 .9 <.001 .03
Gender
Male 4.9 4.6 3.8 3.0 3.6 3.6 12.2 11.2
Female 5.3 4.7 4.2 3.1 3.6 3.6 13.2 11.5
* Test
(Gen. × Country)
<.001 .001 1 <.001
Education
Low 4.9 4.4 3.8 2.7 3.6 3.6 12.2 10.7
Middle 5.4 5.3 4.4 3.8 3.7 3.7 13.4 12.7
High 5.7 5.6 4.6 3.9 3.7 3.7 14.0 13.2
* Test
(Edu. × Country)
<.001 <.001 .4 <.001
* P value of a test for a significant interaction between the selected variable and country.Page 7 of 11
(page number not for citation purposes)
BMC Geriatrics 2009, 9:23 http://www.biomedcentral.com/1471-2318/9/23Table 4: Cognitive function in the US and England, 2002
Variable Model 1 Model 2 Model 3 Model 4
Country (England = Ref) 1.43* (1.3 – 1.6) 1.46* (1.3 – 1.6) 1.30* (1.1 – 1.4) 1.35* (1.2 – 1.5)
Age
65 – 74 Ref. Ref. Ref.
75 – 84 -1.70* (-1.9 – -1.5) -1.63* (-1.8 – -1.4) -1.55* (-1.8 – -1.4)
≥ 85 -3.85* (-4.2 – -3.5) -3.61* (-3.9 – -3.3) -3.52* (-3.8 – -3.2)
Female gender 1.07* (.9 – 1.3) 1.37* (1.2 – 1.5) 1.32* (1.1 – 1.5)
Education
Low Ref. Ref.
Middle .96* (.7 – 1.2) .94* (.7 – 1.1)
High 1.48* (1.2 – 1.7) 1.45* (1.2 – 1.7)
Net Worth (2002 $s)
≤ 80,000 Ref. Ref.
80,001 – 262,000 .98* (.7 – 1.2) .91* (.6 – 1.2)
> 262,000 1.38* (1.1 – 1.6) 1.26* (1.0 – 1.5)
Cardiovascular Risks
Stroke -1.0* (-1.4 – -.6)
Diabetes -.39* (-.6 – -.1)
Hypertension -.04 (-.2 – .1)
Heart disease -.19 (-.4 – .1)
Variable Model 5 Model 6 Model 7 Model 8
Country (England = Ref) 1.33* (1.2 – 1.5) 1.16* (1.0 – 1.3) 1.43* (1.3 – 1.6) 1.43* (1.3 – 1.6)
Age
65 – 74 Ref. Ref. Ref. Ref.
75 – 84 -1.56* (-1.8 – -1.4) -1.53* (-1.7 – -1.3) -1.50* (-1.7 – -1.3) -1.5* (-1.7 – -1.3)
≥ 85 -3.52* (-3.8 – -3.2) -3.45* (-3.7 – -3.2) -3.37* (-3.6 – -3.1) -3.4* (-3.6 – -3.1)
Female gender 1.31* (1.1 – 1.5) 1.37* (1.2 – 1.6) 1.43* (1.2 – 1.6) 1.4* (1.2 – 1.6)
Education
Low Ref. Ref. Ref. Ref.
Middle .94 (.7 – 1.2) .89 (.7 – 1.1) .82 (.60 – 1.0) .79 (.6 – 1.0)
High 1.45* (1.2 – 1.7) 1.39* (1.1 – 1.7) 1.31* (1.0 – 1.6) 1.3* (1.0 – 1.6)
Net Worth (2002 $s)
≤ 82,000 Ref. Ref. Ref. Ref.
82,001 – 262,000 .90 (.6 – 1.2) .83 (.6 – 1.1) .77 (.5 – 1.0) .73 (.5 – 1.0)
> 262,000 1.25* (1.0 – 1.5) 1.15 (.9 – 1.4) 1.04 (.8 – 1.3) 1.0 (.8 – 1.3)
Cardiovascular Risks
Stroke -.99* (-1.4 – -.6) -.96* (-1.3 – -.6) -.91* (-1.3 – -.6) -.89* (-1.2 – -.6)
Diabetes -.12 (-.6 – .4) -.11 (-.6 – .4) -.07 (-.5 – .4) -.01 (-.46 – .43)
Hypertension -.55* (-.9 – -.2) -.46* (-.8 – -.1) -.46* (-.8 – -.1) -.49* (-.84 – -.15)
Heart disease -.19 (-.4 – .1) -.13 (-.4 – .12) -.10 (-.3 – .1) -.10 (-.33 – .13)
Hypertension Treatment .56* (.2 – .9) .50* (.1 – .8) .50* (.1 – .8) .52* (.2 – .9)
Diabetes Treatment
No Treatment Ref. Ref. Ref. Ref.
Only Oral Medication -.29 (-.8 – .2) -.28 (-.8 – .2) -.25 (-.7 – .2) -.25 (-.7 – .2)Page 8 of 11
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such as hypertension, hypercholesterolemia, and obesity
leads to improved brain health among older adults could
pay significant public health dividends.
The strengths of our study include the large nationally rep-
resentative samples of adults in the US and England, and
the direct assessment of cognition using the same cogni-
tive tests administered in the same year. There are also a
number of potential limitations of our study that are
important to consider when interpreting our results. First,
while both the HRS and ELSA are nationally representa-
tive samples, differences between the two studies in over-
all response rates, and in methods for the recruitment of
proxy respondents to answer for sample members, could
have important implications for the comparison of cogni-
tive function of those included in our analysis. The overall
response rate among all eligible respondents was 87% for
the HRS in 2002 and 67% for ELSA. The HRS also
included more proxy respondents compared to ELSA in
2002. Among white respondents aged 65 and older in
2002, 1,171 (12%) were represented by a proxy in the
HRS, compared to only 96 (2%) in ELSA. If the difference
in proxy representation between the two studies is due to
the HRS being more likely to use a proxy for a respondent
with impaired cognitive function (whereas the ELSA
would still use a self-report interview), this could lead to
the pattern of better apparent cognitive performance
among the HRS self-respondents compared to the ELSA
self-respondents included in our study. To assess this pos-
sibility, we compared the characteristics of respondents
represented by a proxy in the HRS and ELSA in 2002, and
did not find evidence that HRS respondents represented
by a proxy were "sicker" or more likely to have impaired
cognition than those in the ELSA. For instance, compared
to ELSA proxies, HRS proxies represented individuals who
were younger (81% were aged < 85 in HRS compared to
61% in ELSA, P < .01) and had higher net worth (31% in
the top tertile in the HRS, compared to 24% in ELSA, P <
.05). In addition, proxies in the HRS rated the overall cog-
nitive function of those whom they represented as some-
what better than ELSA proxies using the same informant
scale (the Informant Questionnaire for Cognitive Decline
in the Elderly.[37] Taken together, these comparisons of
respondents represented by a proxy in the two studies sug-
gest that the poorer cognitive performance of English
adults in our study is not an artifact of differences in the
utilization of proxy respondents.
While the same cognitive tests were administered in both
the HRS and ELSA, one important difference in the
administration of the test should be considered when
interpreting the results. About 70% of the HRS sample
was interviewed by telephone and 30% in-person, while
all ELSA interviews were in-person. If telephone adminis-
tration of the cognitive tests is associated with systemati-
cally better performance compared to in-person
administration, this could explain some of the HRS cogni-
tive advantage that we found. However, two prior studies
have examined the impact of telephone vs. face-to-face
administration of the HRS cognitive tests, and found no
significant differences in test scores for the different survey
modes.[38,39] Finally, it should be noted that our OLS
regression analysis may not have accurately identified
non-linear relationships between the predictor variables
and the cognitive score outcome.
Insulin +/- Oral Med -.57 (-1.3 – .1) -.56 (-1.2 – .1) -.49 (-1.2 – .2) -.50 (-1.2 – .2)
CES-D symptoms
0 Ref. Ref. Ref.
1–3 -.44* (-.6 – -.3) -.41* (-.6 – -.2) -.42* (-.6 – -.2)
4–8 -.93* (-1.2 – -.7) -.88* (-1.1 – -.6) -.88* (-1.1 – -.6)
Alcohol
0 Ref Ref
< 1 0.74* (.5 – 1.0) 0.75* (.5 – 1.0)
>1 to 2 0.71* (.4 – 1.0) 0.72* (.4 – 1.0)
>2 0.50* (.2 – .8) 0.51* (.2 – .8)
Smoking Status
Never Ref.
Former -.11 (-.3 – .1)
Current -.20 (-.5 – .1)
Other Chronic Conditions
Lung disease .06 (-.2 – .3)
Cancer .11 (.-1 – .3)
* P <.05
Table 4: Cognitive function in the US and England, 2002 (Continued)Page 9 of 11
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In conclusion, we found that despite a higher prevalence
of cardiovascular risks and cardiovascular disease among
older US adults, they performed significantly better than
their English counterparts on tests of memory, suggesting
an advantage in cognitive health in the United States.
While we were unable to confidently identify the cause or
causes of this US advantage, higher levels of education
and wealth, lower levels of depressive symptoms, and
more aggressive treatment of cardiovascular risks such as
hypertension, may be important contributing factors.
Given the growing number of older adults worldwide,
future cross-national studies aimed at identifying the
medical and social factors that might prevent or delay cog-
nitive decline in older adults would make important and
valuable contributions to public health.
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